CL2023003168A1 - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
CL2023003168A1
CL2023003168A1 CL2023003168A CL2023003168A CL2023003168A1 CL 2023003168 A1 CL2023003168 A1 CL 2023003168A1 CL 2023003168 A CL2023003168 A CL 2023003168A CL 2023003168 A CL2023003168 A CL 2023003168A CL 2023003168 A1 CL2023003168 A1 CL 2023003168A1
Authority
CL
Chile
Prior art keywords
trex1
modulators
compositions
compounds
variety
Prior art date
Application number
CL2023003168A
Other languages
English (en)
Inventor
Julian R Levell
Jonathan E Wilson
Aaron Coffin
Mary-Margaret Zablocki
Avinash Khanna
David J Guerin
William T Mcelroy
Jennifer L Rocnik
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CL2023003168A1 publication Critical patent/CL2023003168A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)

Abstract

Compuestos de Fórmula (I):(I); y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para el tratamiento de una variedad de condiciones asociadas con la TREX1.
CL2023003168A 2021-04-26 2023-10-24 Moduladores de trex1 CL2023003168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179723P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
CL2023003168A1 true CL2023003168A1 (es) 2024-04-12

Family

ID=81598085

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003168A CL2023003168A1 (es) 2021-04-26 2023-10-24 Moduladores de trex1

Country Status (16)

Country Link
EP (1) EP4330254A1 (es)
JP (1) JP2024517715A (es)
KR (1) KR20240028979A (es)
CN (1) CN117545754A (es)
AR (1) AR125448A1 (es)
AU (1) AU2022264711A1 (es)
BR (1) BR112023022298A2 (es)
CA (1) CA3216752A1 (es)
CL (1) CL2023003168A1 (es)
CO (1) CO2023015732A2 (es)
CR (1) CR20230542A (es)
DO (1) DOP2023000236A (es)
EC (1) ECSP23088732A (es)
IL (1) IL308016A (es)
TW (1) TW202309019A (es)
WO (1) WO2022232004A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
CA3122093A1 (en) * 2018-12-06 2020-06-11 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
KR20240028979A (ko) 2024-03-05
JP2024517715A (ja) 2024-04-23
ECSP23088732A (es) 2024-02-29
CR20230542A (es) 2024-03-19
DOP2023000236A (es) 2024-02-29
WO2022232004A1 (en) 2022-11-03
AU2022264711A1 (en) 2023-11-09
CA3216752A1 (en) 2022-11-03
AR125448A1 (es) 2023-07-19
BR112023022298A2 (pt) 2023-12-26
TW202309019A (zh) 2023-03-01
EP4330254A1 (en) 2024-03-06
CO2023015732A2 (es) 2024-02-05
CN117545754A (zh) 2024-02-09
IL308016A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CL2021001461A1 (es) Moduladores de trex1
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
DOP2016000017A (es) Nuevos compuestos tricíclicos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
UY35362A (es) Compuestos terapéuticos
ECSP10010657A (es) Nuevos compuestos tricíclicos
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
CO2020013840A2 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
ECSP23088732A (es) Moduladores de trex1
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CO2022004305A2 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CU20220025A7 (es) Inihibidores del factor d del complemento para administración oral
CO2023016367A2 (es) Moduladores de trex1
CO2021017202A2 (es) Compuestos tricíclicos
ECSP23075535A (es) Compuestos cíclicos y métodos de uso